• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ocular Therapeutix, Inc. - Common Stock (NQ:OCUL)

9.430 +0.060 (+0.64%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,294,140
Open 9.370
Bid (Size) 9.350 (100)
Ask (Size) 9.450 (200)
Prev. Close 9.370
Today's Range 9.160 - 9.520
52wk Range 6.230 - 16.44
Shares Outstanding 157,749,490
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
1 Healthcare Stock with Exciting Potential and 2 Facing Headwinds
April 02, 2026
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have ou... 
Via StockStory
News headline image
Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools ↗
March 18, 2026
Spyre Therapeutics focuses on antibody therapies for inflammatory bowel disease, advancing a pipeline aimed at gastrointestinal health. 
Via The Motley Fool

Performance

YTD
-20.2%
-20.2%
1 Month
+11.1%
+11.1%
3 Month
+3.1%
+3.1%
6 Month
-17.4%
-17.4%
1 Year
+7.2%
+7.2%

More News

Read More
News headline image
What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down ↗
March 18, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
1 Cash-Heavy Stock to Research Further and 2 We Brush Off
March 18, 2026
Via StockStory
News headline image
3 Reasons to Avoid OCUL and 1 Stock to Buy Instead
March 17, 2026
Via StockStory
News headline image
3 Stocks Under $10 We Think Twice About
March 16, 2026
Via StockStory
News headline image
Pharmaceuticals Stocks Q4 Highlights: Ocular Therapeutix (NASDAQ:OCUL)
March 11, 2026
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 Small-Cap Stocks We’re Skeptical Of
March 05, 2026
Via StockStory
News headline image
3 of Wall Street’s Favorite Stocks We’re Skeptical Of
March 04, 2026
Via StockStory
News headline image
Ocular Therapeutix (OCUL) Stock Trades Down, Here Is Why
February 27, 2026
Via StockStory
Topics Economy Stocks
News headline image
1 Russell 2000 Stock Worth Investigating and 2 We Avoid
February 26, 2026
Via StockStory
News headline image
1 Volatile Stock for Long-Term Investors and 2 Facing Challenges
February 18, 2026
Via StockStory
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
February 17, 2026
Via Chartmill
Tuesday's pre-market session: top gainers and losers ↗
February 17, 2026
Via Chartmill
News headline image
Nasdaq, S&P 500 Futures Lower As AI Disruption Fears Linger: Why AAPL, ZIM, OCUL, NCLH Are On Traders' Radar Today ↗
February 17, 2026
Via Stocktwits
Topics Artificial Intelligence ETFs Economy
News headline image
OCUL Stock Surges Overnight Ahead Of Crucial Wet AMD Data Readout, Sanofi Takeover Buzz Builds ↗
February 16, 2026
Via Stocktwits
Wondering what's happening in today's after-hours session? ↗
February 16, 2026
Via Chartmill
News headline image
Sanofi Tightens Grip on Ocular Therapeutix with Revised Bid as Pivotal SOL-1 Trial Results Loom
February 16, 2026
Via MarketMinute
News headline image
Retina’s ‘Sustained’ Moment: Ocular Therapeutix Braces for Game-Changing Phase 3 AXPAXLI Data
February 16, 2026
Via MarketMinute
News headline image
Ocular Therapeutix (NASDAQ:OCUL) Misses Q4 CY2025 Revenue Estimates
February 05, 2026
Via StockStory
Topics Artificial Intelligence
News headline image
A Look Back at Pharmaceuticals Stocks’ Q3 Earnings: Ocular Therapeutix (NASDAQ:OCUL) Vs The Rest Of The Pack
January 26, 2026
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 Cash-Burning Stocks We’re Skeptical Of
January 19, 2026
Via StockStory
Topics Bankruptcy
News headline image
1 Healthcare Stock to Consider Right Now and 2 We Find Risky
January 15, 2026
Via StockStory
Topics Stocks
What's going on in today's pre-market session ↗
January 15, 2026
Via Chartmill
News headline image
Why Did OCUL Stock Jump 13% In Pre-Market Today? ↗
January 15, 2026
Via Stocktwits

Frequently Asked Questions

Is Ocular Therapeutix, Inc. - Common Stock publicly traded?
Yes, Ocular Therapeutix, Inc. - Common Stock is publicly traded.
What exchange does Ocular Therapeutix, Inc. - Common Stock trade on?
Ocular Therapeutix, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Ocular Therapeutix, Inc. - Common Stock?
The ticker symbol for Ocular Therapeutix, Inc. - Common Stock is OCUL on the Nasdaq Stock Market
What is the current price of Ocular Therapeutix, Inc. - Common Stock?
The current price of Ocular Therapeutix, Inc. - Common Stock is 9.430
When was Ocular Therapeutix, Inc. - Common Stock last traded?
The last trade of Ocular Therapeutix, Inc. - Common Stock was at 05/01/26 04:00 PM ET
What is the market capitalization of Ocular Therapeutix, Inc. - Common Stock?
The market capitalization of Ocular Therapeutix, Inc. - Common Stock is 1.49B
How many shares of Ocular Therapeutix, Inc. - Common Stock are outstanding?
Ocular Therapeutix, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap